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Abstract Parkinson’s disease (PD) is a neurodegenera-
tive disorder frequent at old age characterized by atrophy
of the nigrostriatal projection. Overexpression and A53T-
mutation of the presynaptic, vesicle-associated chaperone
alpha-synuclein are known to cause early-onset autosomal
dominant PD. We previously generated mice with trans-
genic overexpression of human A53T-alpha-synuclein
(A53T-SNCA) in dopaminergic substantia nigra neurons as
a model of early PD. To elucidate the early and late effects
of A53T-alpha-synuclein on the proteome of dopaminergic
nerve terminals in the striatum, we now investigated
expression proﬁles of young and old mice using two-
dimensional ﬂuorescence difference in gel electrophoresis
(2D-DIGE) and mass spectrometry. In total, 15 proteins
were upregulated and 2 downregulated. Mice before the
onset of motor anomalies showed an upregulation of the
spot containing 14-3-3 proteins, in particular the epsilon
isoform, as well as altered levels of chaperones, vesicle
trafﬁcking and bioenergetics proteins. In old mice, the
persistent upregulation of 14-3-3 proteins was aggravated
by an increase of glial ﬁbrillary acidic protein (GFAP)
suggesting astrogliosis due to initial neurodegeneration.
Independent immunoblots corroborated GFAP upregula-
tion and 14-3-3 upregulation for the epsilon isoform, and
also detected signiﬁcant eta and gamma changes. Only
for 14-3-3 epsilon a corresponding mRNA increase was
observed in midbrain, suggesting it is transcribed in
dopaminergic perikarya and accumulates as protein in
presynapses, together with A53T-SNCA. 14-3-3 proteins
associate with alpha-synuclein in vitro and in pathogno-
monic Lewy bodies of PD brains. They act as chaperones
in signaling, dopamine synthesis and stress response. Thus,
their early dysregulation probably reﬂects a response to
alpha-synuclein toxicity.
Keywords 14-3-3 protein  A53T-alpha-synuclein
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder
mostly of elderly people which displays characteristic
motor symptoms including muscular rigidity, resting tre-
mor, slowing of movements and postural instability. The
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DOI 10.1007/s00702-011-0717-3main cause of these motor symptoms is the progressive loss
of the pigmented dopaminergic neurons of the substantia
nigra (SN) pars compacta (Fahn 2003) which project to the
striatum, whereas non-motor symptoms, such as hyposmia,
sleep disorder, autonomic dysfunctions, depression and
dementia mirror the progressive neuronal loss which starts
from the enteric, autonomic and olfactory nervous systems
via the brainstem to the cortex (Braak et al. 2003).
While the molecular causes are currently unknown in
most cases of old-age PD, the underlying genetic factors
have been elucidated in some rare familial cases, usually
with earlier disease onset (Gasser 2001; Huang et al. 2004).
In the past 13 years, 16 genes or chromosomal loci
(PARK1-16) have been linked to familial PD, commencing
with the discovery of an A53T missense mutation in the
alpha-synuclein gene (SNCA) (Polymeropoulos et al. 1997)
and the later description of SNCA gene duplication and
triplication events as the cause of autosomal dominant
early-onset PD (Singleton et al. 2003). Also for the patho-
genesis of late-onset PD, a central role of alpha-synuclein
was established by the observation that the majority of brain
autopsies show pathological aggregation of alpha-synuclein
as the main component of Lewy bodies (LBs) and Lewy
neurites (Spillantini et al. 1997) in the absence of any
SNCA mutations. Abnormal protein-inclusion bodies con-
taining alpha-synuclein have since been demonstrated in
several other neurodegenerative diseases, and alpha-
synuclein aggregates are now the deﬁning molecular feature
for one class of human neurodegenerative diseases, the
synucleinopathies (reviewed in Maries et al. 2003).
Alpha-synuclein is mainly a neuronal protein of 140
amino acids and is primarily concentrated in the nerve
terminals both in soluble form and in association with
membranes, especially with synaptic vesicles (Clayton and
George 1998). The reversible binding to lipid membranes
is mediated by the alpha-helical N-terminal domain con-
sisting of seven repeats of 11-amino acids (consensus
sequence XKTKEGVXXXX) (Bussell and Eliezer 2003).
Alpha-synuclein was claimed to act as a small molecular
chaperone assisting the SNARE (soluble N-ethylmaleimide
sensitive fusion protein attachment receptor) protein com-
plex during rapid rounds of vesicle exocytosis to refold into
the necessary conformation (Chandra et al. 2005). Inter-
estingly, the currently known missense mutations of SNCA
(A30P, A53T, E46K) are situated in the lipid-binding
motifs and are thought to facilitate a conformational shift
from an alpha-helical to a beta-sheet structure (Narhi et al.
1999) that strengthens its association to synaptic vesicles,
favors ﬁbrillation and may ﬁnally lead to protein deposition
(Conway et al. 1998; Kessler et al. 2003). The beta-sheet
containing alpha-synuclein oligomers or ﬁbrils, rather than
the insoluble inclusion bodies such as LBs, were proposed
to mediate the neurotoxicity via formation of pore-like
structures that permeabilize membranes (Volles and
Lansbury 2003), a process which might lead to pathologi-
cal neurotransmission as well as affect mitochondria.
Alpha-synuclein toxicity appears aggravated by mito-
chondrial dysfunction, oxidative stress, and ﬁnally leads to
neurodegeneration (Schapira and Tolosa 2010).
The aggregation of alpha-synuclein and the process of
neurodegeneration are mitigated in transgenic mice, where
the mutant human alpha-synuclein protein coexists with the
wild-type (WT) murine alpha-synuclein (Cabin et al.
2005). Indeed, our alpha-synuclein transgenic mouse lines
do not show the end-stage features of human PD such as
loss of nigrostriatal dopaminergic neurons and alpha-syn-
uclein aggregates visible by light microscopy in affected
neurons (Kahle et al. 2001; Gispert et al. 2003). They were
selected in view of their approximately 1.5-fold overex-
pression of A53T-SNCA driven by the neuronal PrP pro-
moter in the substantia nigra dopaminergic projection
neurons and their absence of transgene expression from
striatal neurons, with the aim to dissect the functional
anomalies of the dopaminergic nerve terminals and post-
synaptic neurons in the striatum prior to the onset of
structural pathology. These mice have an interesting
phenotype, since they display progressive Parkinsonian
features such as impairment of spontaneous motor activity
from the age of 6 months onward (Gispert et al. 2003).
This locomotor syndrome correlates with progressive
changes in the striatum, where an abnormally high DA
content is accompanied by postsynaptic and glial efforts to
maximize the DA signal suggesting a neurotransmission
deﬁcit in the presynaptic compartment. The cellular com-
pensatory efforts appear insufﬁcient, since a progressive
loss of corticostriatal synaptic plasticity is observed (Kurz
et al. 2010). A global transcriptome proﬁle of the striatum
in these mice at old age corroborated the prominent sig-
naling alteration, demonstrated a reduced DA response of
postsynaptic neurons and detected early changes in cell
adhesion and in protein aggregation pathways (Kurz et al.
2010).
Since a global description of the protein network
changes underlying this synaptic dysfunction in response
to alpha-synuclein toxicity is lacking, we aimed to docu-
ment the proteome of the striatal target region of the
dopaminergic nigrostriatal nerve terminals by application
of two-dimensional difference gel electrophoresis
(2D-DIGE). 2D-DIGE is a powerful method to differen-
tially display dysregulated proteins in a complex biological
context. We assessed the progression of proteome changes
from the early adult age of 6 months to the advanced age of
22 months, and identiﬁed in total 17 dysregulated proteins
by mass spectrometry.
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Mice
Transgenic mice (the PrPmtA line on the inbred FVB/N
background) expressing the human A53T-SNCA cDNA
under control of the murine neuron-speciﬁc PrP promoter
(Gispert et al. 2003) were used for differential proteome
studies. The mice were housed at the FELASA-certiﬁed
Central Animal Facility (ZFE) of Frankfurt Goethe Uni-
versity Medical School according to the animal husbandry
guidelines of the German Animal Welfare Act, the Council
Directive of 24 November 1986 (86/609/EWG) with Annex
II and the ETS123 (European Convention for the Protection
of Vertebrate Animals). All the experiments were con-
ducted in conformity with the European Communities
Council Directive of November 1986 (86/609/ECC).
The mice were bred to homozygosity and housed in
individually ventilated cages under special-pathogen-free
conditions. Studies were performed in 6 and 22 month-old
mice and the respective age- and sex-matched controls
(male, wild-type FVB/N, n = 5 each). After cervical dis-
location, animals were decapitated, brains removed, striatal
tissue dissected, directly frozen in liquid nitrogen, stored at
-80C and shipped on dry ice.
Dissection of striatum and midbrain
Immediately after the removal of the brain, an anterior
block was isolated (including olfactory bulb, frontal cortex,
striatum, thalamus, hypothalamus) by a coronal cut through
the median eminence of the hypothalamus. The easily
distinguishable structure of striatum and accumbens was
separated from the surrounding cortex and basal ganglia
using a curved forceps along axon bundles. In the corre-
sponding posterior block, the remaining cortex and hip-
pocampus was removed, a cut from the median eminence
to the upper end of the superior colliculi was carried out,
and the midbrain was isolated from brainstem and cere-
bellum with a second cut above the pons, according to the
mouse brain atlas of Paxinos and Franklin (Paxinos and
Franklin 2001).
Protein extraction and labeling
For 2D-DIGE, frozen tissue samples were transferred to a
mortar cooled with liquid nitrogen, incubated with 1.2
volumes of lysis buffer (7 M urea, 2 M thiourea, 4%
CHAPS, 30 mM Tris, pH 8.5) and ground to a ﬁne powder.
The suspension was transferred to a 1.5-ml reaction tube
and mixed for 30 min at 4C. The homogenate was cen-
trifuged (30 min, 4C, 226,000 g) (centrifuge: Beckman
Optima, rotor: MLT130, 65,000 rpm) and the supernatant
was carefully transferred to a 1.5-ml empty reaction tube.
The pellet was poured back into the mortar, incubated with
1.2 volumes of lysis buffer and ground again. The process
was repeated as described above and both supernatants were
combined. The collected supernatants were extensively
mixed and centrifuged again under the described condi-
tions. The resulting supernatant was used for labeling after
protein determination. The tagging of the proteins using the
CyDye minimal dyes (GE Healthcare, Freiburg, Germany)
was performed essentially according to Sitek et al. (2005).
In brief, the dyes were added to the protein extract (8 pmol/g
protein). An internal standard was prepared from all sam-
ples (equivalent amounts) included in this study and labeled
with Cy2. After vortexing, centrifugation, and incubation
(0.5 h in the dark), 10 mM L-lysine (1 L-lysine/400 pmol
dye) (Sigma, St. Louis, USA) were admixed to stop the
reaction (10 min in the dark). A potential dye bias as
described by (Karp et al. 2007) was excluded by performing
a preceding same–same experiment.
Two-dimensional ﬂuorescence difference in gel
electrophoresis
Proteins were separated by 2D-PAGE (polyacrylamide gel
electrophoresis) essentially according to the method
described by Stuhler et al. (2006). After rehydration of the
IPG(immobilizedpHgradient)-strips(24 cm,pH3–11,NL)
inrehydration buffer overnight(8 Murea,2 Mthiourea,2%
CHAPS, 0.8% Servalyte, 100 mM DTT) the ﬂuorescently
tagged proteins were loaded via cup loading (150 lgo f
protein, 50 lg of each labeled sample). Following focusing
(atmax.20Cfor110 kVhasfollows:6 hat100 V/step,1 h
at 300 V/gradient, 3 h at 300 V/step, 6 h at 1,000 V/gradi-
ent, 1.5 h at 6,000 V/gradient, 16 h at 6,000 V/step) and
equilibration (15 min in equilibration buffer A: pH 8.8, 6 M
urea, 50 mM Tris, 2% SDS, 30% glycerin, 65 mM DTT,
15 min in equilibration buffer B: pH 8.8, 15 min in equili-
brationbuffer,pH8.8,6 Murea,50 mMTris,2%SDS,30%
glycerin, 280 mM iodoacetamide), the IPG-strips were
transferred to the top of a 12% SDS polyacrylamide gel
(20 9 30 9 7 cm), sealed with agarose sealing solution
(50 mM Tris–HCl, 0.1%SDS, 192 mM glycine, 0.3% (w/v)
agarose, bromophenol blue) and run on a Desaphor VA 300
system (Klose and Kobalz 1995) at 75 mA per two gels at
20C. The internal standard was a mixture of lysates from
A53T-alpha-synuclein mice and control mice of one age
stage. It implies there were in total two internal standards
one for the 6 and one for the 22-month-old mice.
Scanning and image analysis
Gels were scanned using a Typhoon 9400 scanner (GE
Healthcare). Excitation and emission wavelengths were
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123chosen speciﬁcally for each dye according to the manufac-
turer’s recommendations. Images were preprocessed using
the ImageQuant
TM
software. Intra-gel spot detection and
inter-gel matching were performed using the Differential
In-gel Analysis mode (Butor et al. 1993) and Biological
Variation Analysis (BVA) mode of DeCyder
TM
software
(all GE Healthcare), respectively. The spot intensities were
normalized and differentially expressed protein spots were
determined applying Student’s t test by pair-wise compari-
son of the transgenic with the respective control data. Every
protein spot with p B 0.05 and reproducible expression
change in at least four of ﬁve independent experiments was
considered as signiﬁcantly differentially expressed and was
subsequently analyzed by mass spectrometry (MS).
Protein identiﬁcation by mass spectrometry
Protein spots were excised from the gel, washed, tryptically
(Promega, Madison, WI, USA) digested overnight as
described previously (Schaefer et al. 2003, 2006) and
sequenced by MALDI-TOF/TOF–MS (matrix-assisted
laser desorption/ionization—time-of-ﬂight—mass spectro-
metry) and nanoLC–ESI–MS/MS (liquid chromatography
directly coupled to electrospray ionization/tandem mass
spectrometry).
MALDI-TOF/TOF–MS
Peptide extraction was done by sonication for 15 min in
15 ll 0.1% triﬂuoroacetic acid (TFA) followed by repeated
extraction with 15 ll 0.1% TFA/100% ACN (acetonitrile)
in case of MALDI-TOF/TOF analysis using the Ultraﬂex II
(Bruker Daltonik, Bremen, Germany). The MALDI target
was prepared as follows: ten microliters of a-cyano-
4-hydroxycinnamic acid (HCCA) saturated matrix solution
(in 97% acetone/3% TFA) was added to the anchor chip
target and constantly drawn over 24 anchor positions. One
microliter of the peptide extract was pipetted onto one
prepared anchor. The dried sample was recrystallized using
0.7 ll recrystallisation solution (6:3:1, ethanol:acetone:
washing solution; washing solution: 10 mM NH4H2PO4,
0.1% TFA) and subsequently washed for 1 min with a
small droplet of washing solution. MALDI-TOF/TOF–MS
analyses were performed using the following parameters:
target-voltage: 25 kV, acceleration voltage: 21.8 kV,
reﬂector voltage: 26.3 kV, detector voltage: 13.9 kV, lens
voltage: 10.35 kV, laser-offset: 68 ? 15%. MS- and frag-
mentation spectra were recorded manually. Data were
collected using ProteinScape
TM
(Bruker Daltonik) (Cham-
rad et al. 2003; Stephan et al. 2006). Peptide mass ﬁnger-
printing (PMF) spectra interpretation was done using the
Profound (Zhang and Chait 2000) and Mascot (Perkins
et al. 1999) algorithms with the following parameters:
50 ppm mass tolerance, tryptic digest, two missed cleavage
sites, carbamidomethylation at cysteine residues (?57 Da)
(ﬁxed), oxidation of methionine (variable). Proteins were
considered as identiﬁed if the MetaScore (ProteinScape)
(Chamrad et al. 2003) was higher than 3.0. Fragmentation
spectra were analyzed with the SEQUEST
TM
(Turbo-
SEQUEST v3.2) (Eng et al. 1994; Yates et al. 1995) and
Mascot (version 2.0.0.4) search algorithms, respectively.
The mass tolerance was set to 0.5 Da both for parent ions
and fragment ions and the other parameters were set as
described above. All searches were performed using the
IPI.mouse.V3.05 protein sequence database (http://www.
ebi.ac.uk/IPI/).
NanoLC–ESI–MS/MS
The extracted peptides were ﬁrst pre-concentrated (0.3 mm
i.d. 9 1 mm, PepMap-column) and separated (75 lm
i.d. 9 150 mm, PepMap column) on the Ultimate HPLC
System consisting of Famos
TM
, Switchos
TM
and Ultimate
TM
(all Dionex LC Packings, Idstein, Germany) online coupled
to a Finnigan LCQdeca XP ion trap mass spectrometer
(ThermoElectron Finnigan, San Jose, USA). The parame-
ters used for nanoLC–ESI–MS/MS were already described
in detail (Schaefer et al. 2004). ESI-MS/MS-spectra that
are not interpreted were correlated with the IPI.mou-
se.v3.71 protein sequence database (http://www.ebi.ac.uk/
IPI/) applying both the Mascot (version 2.0.0.4) and the
SEQUEST
TM
(TurboSEQUEST v3.2) algorithm with the
same parameters as described above considering a mass
tolerance of ±1.5 Da for both parent and fragment ions.
Proteins were considered to be identiﬁed if at least two
peptides were explained by the spectra and if the
SEQUESTMetaScore (ProteinScape) was higher than 3.0.
Immunoblotting—chemiluminescent detection
of 14-3-3
Following tissue homogenization with radioimmunopre-
cipitation assay (RIPA), buffer (50 mM TRIS pH 8.0,
150 mM NaCl, 1% Triton X-100, 0.5% Na-deoxycholate,
0.1% SDS) supplemented with complete protease inhibitor
cocktail (Roche, Mannheim, Germany), samples were
incubated at 4C, rotating for 20 min. Homogenates were
centrifuged at 4C for 15 min at 4,500 g and supernatants
were collected. Twenty micrograms of protein were sepa-
rated in 10% tris–glycine polyacrylamide gels and trans-
ferred onto a polyvinylidene ﬂuoride (PVDF) membrane
(Bio-Rad, Munich, Germany). Membranes were blocked
for 1 h at room temperature (RT) in a commercially
available ready-to-use blocking buffer (Rockland Immu-
nochemicals Inc., Gilbertsville, PA, USA) and incubated
with the primary antibodies (dilution 1:1,000) for the
300 A. Kurz et al.
123speciﬁc 14-3-3 protein isoforms [anti-14-3-3 epsilon
(#sc-1020), anti-14-3-3 beta/alpha (#9636), anti-14-3-3 gamma
(#9637), anti-14-3-3 tau (#9638), anti-14-3-3 zeta/delta
(#9639) and anti-14-3-3 eta (#9640); with the exception of
the 14-3-3 epsilon antibody (Santa Cruz Biotechnology/
Santa Cruz, CA, USA)], all 14-3-3 antibodies were
obtained from Cell Signaling Technology
/Danvers, MA,
USA) or anti-beta-actin (dilution 1:15,000; (#A5441),
Sigma-Aldrich/Hamburg, Germany) in ready-to-use
blocking buffer at 4C overnight (ON), washed thrice with
PBS/Tween (0.1%) and incubated with the secondary
antibody (alkaline phosphatase conjugated anti-rabbit
antibody, 1:15,000 dilution (#NA934V, GE Healthcare,
Munich, Germany) for 1 h at RT. After washing, the sec-
ondary antibody was detected with a chemiluminescent
substrate (Pierce SuperSignal West Pico Chemilumines-
cent; Thermo Fisher Scientiﬁc Inc., Rockford, IL, USA).
Densitometric analyses utilized TotalLab software (v.2.0;
Amersham Biosciences, Freiburg, Germany).
Immunoblotting—infrared detection of GFAP,
beta-actin, alpha-synuclein
Five microgramsofproteinlysatewereseparatedusing10%
Bis–Trisgelsaccordingtomanufacturer’srecommendations
(Invitrogen, Karlsruhe, Germany). Proteins were electro-
transferred to nitrocellulose membranes using semidry-
blotting with a discontinuous buffer system and incubated
in StartingBlock
TM
(Pierce, Woburn, MA, USA) for 2 h.
Primary antibodies were diluted in TBS-buffer, the nitrocel-
lulosemembranes probedwiththe primary antibodiesfor 1 h
and washed in TBS-buffer 39 for 20 min. The membranes
were incubated with the ﬂuorescent secondary antibody
solution (0.59 Starting-Block
TM
) for 1 h and ﬁnally washed
inTBS-buffer 39for20 min.Theﬂuorescencereadoutwas
performed on an Odyssey
TM
(LI-COR Biosciences GmbH,
Bad Homburg, Germany). Beta-Actin was used as internal
standard. Nonlinear data regression was done using the
Origin
TM
softwarepackage(LI-COR).Tocontrolgenotyping
by immunoblot analyses, we applied an anti-human mono-
clonal antibody to alpha-synuclein (clone LB409; 1:2,000;
Zymed
, Invitrogen) as well as the anti-mouse and anti-
human monoclonal antibody to alpha-synuclein (1:2,000;
clone 42; BD Transduction Laboratories
TM
, San Diego, CA,
USA). The anti-glial ﬁbrillary acidic protein (GFAP) poly-
clonal antibody (1:2,000; Z0334) was purchased from
DakoCytomation (Dako Germany GmbH, Hamburg,
Germany), andthe anti-mousemonoclonal antibody tobeta-
actin (1:10,000; clone AC-15) was from Sigma-Aldrich
(Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany).
Secondary anti-mouse IRDye800CW or Alexa
 680 anti-
bodies (1:15,000), as well as the anti-rabbit Alexa
 680
antibody (1:30,000) were obtained from LI-COR.
Immunohistochemistry
Detection of 14-3-3 epsilon was carried out after heat
antigen retrieval either through treatment in a Bull’s Eye
Decloaker (BioCare Medical) (Fig. 5) or through micro-
wave cooking in citrate buffer, with similar results.
Endogenous peroxidase was then blocked with 3%
hydrogen peroxide in Tris–HCl pH 7.6 for 30 min. After
washing with 0.1% Tris–HCl and blocking with 10% goat
serum, 0.5% PBST for 90 min at 25C, sections were
incubated with the primary antibody in 0.1% Tris–HCl
overnight at 4C. After washing with 0.1% Tris–HCl,
sections were incubated with biotinylated goat anti-mouse
(for 14-3-3 epsilon) or anti-rabbit (for GFAP) IgG (1:200;
Vector Laboratories) for 90 min at 25C. After washing
with 0.1% Tris–HCl, sections were then incubated with
Vectastain ABC (Vector Laboratories) for 2 h and ﬁnally
washed with 0.1% Tris–HCl. Peroxidase activity was then
detected with Vector Nova Red SK4800 (Linaris). Pictures
were taken with 209 or 659 (with oil immersion) objec-
tives on an Axiovert 200 m microscope, using an Axiocam
CCD camera and the Axiovision Rel. 4.8 software.
Analyses of transcript levels via qPCR
Total RNA was extracted from midbrain derived from old
mice with TRIZOL (Invitrogen, Karlsruhe, Germany) and
digested with DNase (ampliﬁcation grade I; Invitrogen)
following the manufacturer’s instructions. In case of the
striata derived from old animals, RNeasy Lipid Tissue Mini
Kit (Qiagen, Hilden, Germany) was used for RNA
extraction. Two micrograms of DNase-treated RNA were
reverse transcribed in a 36-ll reaction, using pd(N)6 and
NotI-d(T)18 primers (First Strand cDNA Synthesis Kit;
Amersham Biosciences, Munich, Germany).
For analyses of 14-3-3 protein expression on transcript
level, all qPCR reactions were carried out in a total volume
of 20 ll containing 5 ll cDNA template, 10 ll2 9 Taq-
Man
 Universal Master Mix (Applied Biosystems, Darms-
tadt, Germany) and 1 ll2 0 9 TaqMan
 gene expression
assay(AppliedBiosystems)onanABIPrism5700sequence
detection system (SDS5700; Applied Biosystems).
Expression levels of the transcript for TATA binding
protein (Tbp) were used as endogenous control for nor-
malization. Expression changes were analyzed with the
2
-DDCt method (Livak and Schmittgen 2001). The following
commercially available TaqMan
 assays were employed:
Mm01247811_m1 (Ywhab = 14-3-3 beta transcript),
Mm00777369_m1 and Mm03047428_m1 (Ywhag = 14-3-3
gamma transcript), Mm00494246_m1 (Ywhae = 14-3-3
epsilon transcript), Mm00834297_m1 and Mm01714763_
gH (Ywhah = 14-3-3 eta transcript), Mm01231061_g1
(Ywhaq = 14-3-3 theta transcript), Mm01158417_g1
A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway 301
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(Tbp).
Statistical analysis
Statistical analysis of 14-3-3 validation via Immunoblot-
ting and qPCR was performed using unpaired Student’s
t tests via the Prism 3 software (GraphPad, La Jolla, CA,
USA). Data are presented as mean ± SEM. Signiﬁcant
differences were highlighted with asterisks (*p\0.05).
Results
Our approach to use adult, young and old A53T-alpha-
synuclein overexpressing mouse striatal tissue to study the
global proteome expression changes identiﬁed 17 dysreg-
ulated proteins which represent mainly signaling pathways
as well as vesicle dynamics and bioenergetics.
We applied 2D-DIGE minimal labeling to striatal pro-
tein lysate from mice at age 6 and 22 months, with n = 5
each (control and A53T-alpha-synuclein mice) in order to
exclude effects in differential protein expression due to
general biological variances. Altogether we could identify
17 differentially expressed proteins with consistency and
high statistical relevance (p B 0.05). Fifteen of those pro-
teins were upregulated and two were downregulated
(Fig. 1).
Differential protein spots were picked from the gels,
washed and proteins were tryptically digested. All 17
proteins could be identiﬁed using LC-ESI–MS (Table 1).
Identiﬁed proteins are grouped with respect to a change
in expression at either early (6 months) or late age
(22 months).
Proteome changes at young age
At the age of 6 months, seven non-redundant proteins were
slightly or moderately upregulated in the transgenic com-
pared to control mice, representing different functional
pathways or subcellular localizations:
Changes of 14-3-3 chaperones
The main change concerned the transgenic human A53T-
alpha-synuclein, which was (as expected) absent in con-
trols and strongly expressed in transgenic tissue, while no
signiﬁcant changes were detected for murine endogenous
alpha-synuclein [as observed previously, see Kurz et al.
2010] protein, consistent with unchanged brain mRNA
levels for murine endogenous alpha-synuclein (data not
shown). The 14-3-3 protein spot was found upregulated to
a comparable degree. An even higher upregulation of the
14-3-3 protein spot was observed at the age of 22 months
(Fig. 2a). In the present and previous proteomic studies of
mouse models for neurodegenerative diseases, the effects
of the transgene on the overall brain proteome (even when
analyzing histologically homogeneous regions) produced
relatively low effects [e.g., (Palacino et al. 2004) and own
unpublished results]. Thus, the high regulation factor for
14-3-3 protein suggests an important and selective effect.
To elucidate the identity of 14-3-3 protein isoforms
responding to A53T-alpha-synuclein overexpression,
mass spectrometric analysis was performed and indicated
14-3-3 epsilon to be the differentially expressed isoform
(Fig. 2a/b).
Changes of proteins involved in synaptic vesicle trafﬁcking
For all other proteins, much smaller expression change
ratios were observed in comparison, but always a consis-
tent upregulation was found (Table 1). The elevated levels
of vesicle ﬁssion protein dynamin-1 isoform 4 that medi-
ates endocytosis (Ferguson et al. 2007) can be expected to
affect signaling, similar to 14-3-3. An upregulation was
Fig. 1 2D-DIGE gel of striatal cell lysate 2D-DIGE of cytosolic
whole-cell striatal lysate (150 lg) of A53T-alpha-synuclein-over-
expressing mice (PrPmtA line on the inbred FVB/N background)
versus controls after CyDye minimal ﬂuorescent labeling revealed in
total 17 protein spots (indicated by arrows) with a signiﬁcant
expression change. All protein spots could be identiﬁed. The
respective identiﬁcation data are summarized in Table 1
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123also found for Chmp4b (charged multivesicular body pro-
tein 4b) which is implicated in vesicle dynamics.
Changes of proteins related to bioenergetics
Particularly noteworthy were the triosephosphate isomer-
ase (TPI), a protein engaged in glycolysis and the mito-
chondrial tricarboxylic acid cycle, and the glycogen
phosphorylase, which is involved in energy mobilization
from astrocytic glycogen reserves (Wiesinger et al. 1997),
as they both suggest an alteration of glycolytic ﬂux in the
mutant striatal tissue. The upregulation of mitochondrial
ubiquinol-cytochrome C reductase complex 11 kDa protein
also suggests altered bioenergetic turnover.
Proteome changes at late age
At the age of 22 months, 12 non-redundant proteins were
slightly or moderately upregulated and 2 were downregu-
lated compared to controls.
Changes of 14-3-3 chaperones
An even higher upregulation of the 14-3-3 protein spot was
observed at this advanced age (Table 1). To validate this
result, antibodies for all 14-3-3 protein isoforms were
employed in immunoblots in order to assess the expression
levels in old striatum from independent animals (Fig. 3a
and Supplementary Figure 1). A signiﬁcant upregulation
Fig. 2 Detailed description of
the expression changes of 14-3-
3 proteins. a Mass spectrum of a
peptide identifying 14-3-3
epsilon. Mass spectrometric
analysis of the protein spot 2
(see Fig. 1) unequivocally
identiﬁed the epsilon isoform of
14-3-3 protein family based on
the C-terminal peptide sequence
EALQDVEDENQ.
b Alignments of the C-termini
of several 14-3-3 protein
isoforms demonstrate that the
peptide identiﬁed by MS/MS
(a) corresponds to the epsilon
isoform of the 14-3-3 protein
family
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123was conﬁrmed for 14-3-3 epsilon. For further validation,
transcript levels of the different 14-3-3 isoforms were
quantiﬁed in additional animals. Both the striatum and the
midbrain were analyzed, since the axons and the presyn-
aptic compartments of dopaminergic A53T-alpha-synu-
clein-overexpressing neurons projecting to the striatum are
almost devoid of mRNA, while their cell bodies located in
the midbrain are the site of most mRNA translation.
Indeed, a signiﬁcant upregulation was again observed for
the 14-3-3 epsilon isoform with commercial quantitative
real-time reverse-transcriptase-PCR (qPCR) assays in the
midbrain tissue, but not in the striatum (Fig. 3b). Immu-
nohistochemical analyses of striatal tissue at late age were
compatible with a neuronal localization of 14-3-3 epsilon
and showed increased 14-3-3 epsilon signals at the neu-
ronal cytoplasmic rim in transgenic mice (Fig. 5). Thus,
different technical approaches in independent animal
groups all support the selective dysregulation of the 14-3-3
epsilon isoform. The protein levels of 14-3-3 alpha/beta,
gamma, delta/zeta, theta/tau and eta isoforms were also
analyzed, revealing a signiﬁcant upregulation also for 14-
3-3 eta, as well as a signiﬁcant downregulation for 14-3-3
gamma (Fig. 3c). In the midbrain of our A53T-SNCA
mice, the mRNA levels of the gamma, theta and eta 14-3-3
isoforms were not signiﬁcantly altered (data not shown), in
contrast to a previous report on epsilon, gamma and theta
mRNA downregulation in the cortex of transgenic alpha-
synuclein mice (Yacoubian et al. 2011).
Fig. 3 Validation of elevated
14-3-3 epsilon levels. The
overexpression of 14-3-3
epsilon detected in the 2D-
DIGE study was validated with
independent techniques in the
nigrostriatal projection via
immunoblotting and qPCR
analyses. a Analysis of 14-3-3
epsilon protein levels in the
striatum via immunoblotting
conﬁrmed increased 14-3-3
epsilon expression. Beta-actin
was used as endogenous control
for normalization. b Analysis of
14-3-3 epsilon transcript levels
in the midbrain via qPCR
showed signiﬁcantly increased
14-3-3 epsilon expression, while
the levels in the striatum were
not increased. TATA-binding
protein (Tbp) was used as
endogenous control. c Analysis
of protein levels of the different
14-3-3 isoforms in aged
striatum via immunoblotting
demonstrated signiﬁcantly
increased 14-3-3 eta levels and
signiﬁcantly decreased 14-3-3
gamma levels. Data sets were
normalized to the corresponding
WT mean values, Student’s
t test was applied for statistical
analyses and signiﬁcant
alterations were highlighted
with asterisks (*p\0.05).
N = 3–8 animals/genotype,
a shows the combined data
derived from two independent
experiments
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123Changes of aggregation and cytoskeleton proteins
The consistently increased expressions of UCH-L1 (ubiq-
uitin carboxy-terminal hydrolase isoenzyme L1), Psma3
(proteasome subunit alpha type 3), Serpin B1a (serine/
cysteine proteinase inhibitor clade B member 1a, being a
member of a gene family implicated in several conforma-
tional diseases as well as PD, Crowther 2002) and
Mu-crystallin homolog at this advanced age represent
selective changes of protein degradation/aggregation mol-
ecules, and might reﬂect the dysfunction of the ubiquitin/
proteasome system in later stage PD (Olanow and
McNaught 2006). Besides 14-3-3, the upregulated astocytic
cytoskeletal protein glial ﬁbrillary acidic protein (GFAP) in
old transgenic animals compared to control animals rep-
resents the second strong expression change and is of high
interest, since it is a well-established biomarker of astro-
cyte proliferation that responds in a sensitive manner to
neural degeneration processes during aging and in brain
degeneration disorders. This GFAP increase was detected
on 2D gels (Table 1) and validated by immunoblotting
(Fig. 4) as well as immunohistochemistry (Fig. 5). A slight
upregulation was also observed for the actin-cytoskeleton
interactor ezrin.
Discussion
Studying the striatal brain proteome of A53T-alpha-
synuclein overexpressing mice at young and old age with
2D-DIGE and mass spectrometry, we found strong evi-
dence for an early and progressive upregulation of the
molecular chaperone 14-3-3 epsilon suggesting presynaptic
signaling pathology, and a modest upregulation of the
astrocytic cytoskeleton protein GFAP at old age suggesting
some neurodegenerative changes to take place in the stri-
atum of this PD mouse model. Other expression changes
were observed in early adult life for proteins representing
chaperones, vesicle trafﬁcking and bioenergetics pathways,
while changes in protein aggregation pathways became
apparent in later life. Although these changes were too
slight for independent validation by immunoblotting, they
showed consistency in independent mice.
Changes of 14-3-3 chaperones as an early consequence
of alpha-synuclein toxicity
The most relevant result of our study is the upregulation of
14-3-3 epsilon mRNA in the region containing the dopa-
minergic nigral neurons and of the corresponding protein in
the region containing the dopaminergic terminals. 14-3-3
epsilon is known to be associated with synaptic membranes
(Martin et al. 1994), similar to alpha-synuclein (Clayton and
George 1998). Our data also indicate 14-3-3 epsilon to be
transported to the presynapse, possibly in association with
the pathogenic alpha-synuclein, and to follow its expression
change. This seems plausible, since a co-localization
of alpha-synuclein and 14-3-3 protein was previously
observed in homozygous A53T-alpha-synuclein transgenic
mice with severe movement disorder and neuronal synuc-
leinopathy (Shirakashi et al. 2006). Furthermore, in vitro
models showed that elevated alpha-synuclein leads to an
increase of 14-3-3 protein and demonstrated the association
of both proteins within 54–83 kDa complexes which
mediate DA neurotoxicity in susceptible neurons (Xu et al.
2002). Our data are consistent with these ﬁndings and
extend them, indicating that upregulation of the signaling
modulator 14-3-3 protein in response to A53T-alpha-syn-
uclein overexpression is a prominent effect in vivo already
at an age where only subtle behavior impairment is
noticeable, well before the advent of detectable neurode-
generation in the brain. In addition, our data clearly identify
the principal 14-3-3 isoform, while both studies cited above
failed to deﬁne the disease stage and the speciﬁc 14-3-3
protein variants. The 14-3-3 protein family includes six
brain-expressed proteins forming homo- and heterodimers
(beta/alpha, gamma, epsilon, delta/zeta, theta/tau, eta),
which are encoded by different genes (YWHAB, YWHAG,
YWHAE, YWHAZ, YWHAQ, YWHAH). Interestingly,
14-3-3 epsilon was previously found dysregulated also in
mice with deﬁciency of alpha-synuclein (Chandra et al.
2004). This suggests that through their protein interaction,
14-3-3 epsilon senses the physiological function of alpha-
synuclein and responds to any dysfunction by a corre-
sponding expression change. Furthermore, our data show
that 14-3-3 epsilon increases its expression with advancing
pathology, and a previous report found it by immunohis-
tochemistry in the LB halo of PD patient brains (Berg et al.
Fig. 4 Immunoblot analyses of GFAP protein levels in the striatum
of A53T-alpha-synuclein-overexpressing mice. The overexpression of
glial ﬁbrillary acidic protein (GFAP) detected in the 2D-DIGE study
was validated by immunoblotting using Odyssey near-IR detection.
Immunoblot analysis showed a several-fold increase of total GFAP in
the 22-month-aged PrPmtA mice. Beta-actin was used as internal
control, and human alpha-synuclein discriminated transgenic from
WT mice
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Parkinson progression. The relevance of 14-3-3 proteins for
the pathogenesis of PD seems to extend beyond alpha-
synuclein, since they were recently identiﬁed as interactors
of LRRK2, another disease gene responsible of autosomal
dominant PD variants which has been implicated in phos-
pho-signaling (Dzamko et al. 2010; Nichols et al. 2010;
Rudenko and Cookson 2010; Titz et al. 2010). Thus, all
available data point to an important role of this particular
isoform for alpha-synuclein physiological function and for
Parkinson neurotoxicity.
What is the functional impact of this 14-3-3 protein
dysregulation? 14-3-3 proteins are signal transducers and
were initially discovered as biosynthesis activators of
neurotransmitters such as DA, leading to their synony-
mous name tyrosine-3-monooxygenase/tryptophan-5-mono-
oxygenase activation proteins. It is important to note that
14-3-3 proteins share physical and functional properties
with alpha-synuclein (Ostrerova et al. 1999), constituting
possibly the basis for related chaperone functions. They
were detected in protein association with alpha-synuclein
(Xu et al. 2002), and in interaction with tyrosine hydrox-
ylase (TH), the rate-limiting enzyme of DA biosynthesis
(Perez et al. 2002). While 14-3-3 proteins activate TH,
wild-type alpha-synuclein was observed to dose-depen-
dently inhibit TH and DA synthesis (Perez et al. 2002) and
may thus act as an antagonist. The notion of 14-3-3
upregulation to act as a cellular compensation of
Fig. 5 Immunohistochemical validation of upregulated striatal pro-
teins. Striatal tissue from late age animals was analyzed. 14-3-3
epsilon staining showed neuronal immunoreactivity throughout the
cytoplasm in wild-type (a) and A53T-SNCA overexpressing mice
(b) (corpus callosum on the left side and the ventricle below). In the
mutant tissue, the neuronal cytoplasmic staining was enhanced, in
agreement with the proteome results, with stronger signal intensity at
the cell border (see high-magniﬁcation inset). GFAP staining showed
comparable astrogliosis throughout the corpus callosum of wild-type
(c) and mutant (d) aged animals (corpus callosum on the right side
and the ventricle below), while the astrogliosis in the striatum
appeared enhanced in the A53T-SNCA overexpressing mice, again in
concordance with the proteome data
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show the pharmacological inhibition of 14-3-3 proteins to
enhance neurotoxic vulnerability, whereas 14-3-3 overex-
pression in C. elegans has a protective effect (Yacoubian
et al. 2011). These properties of 14-3-3 proteins may exert
a relevant effect in our A53T-alpha-synuclein-over-
expressing mice, since signiﬁcantly elevated striatal DA
levels were previously observed in these animals from the
age of 6 months onward (Kurz et al. 2010), a ﬁnding that
could not be explained by the overexpression of A53T-
alpha-synuclein, but is easily understood as a correlate of
14-3-3 protein upregulation. Thus, our documentation of a
consistent upregulation of 14-3-3 epsilon in 2D-DIGE
analyses, mass spectrometry, immunoblots and qPCRs
explains the previously reported early increase of striatal
DA in these mice. Regarding the contrasting changes of
14-3-3 gamma, which showed decreased protein levels in
the striatum in spite of unchanged mRNA levels in the
substantia nigra, it is possible that this isoform is seques-
tered into insolubility through the aggregation process of
alpha-synuclein detectable in the striatum of our mice
(Kurz et al. 2010).
Changes of proteins involved in synaptic vesicle
trafﬁcking
In the context of synaptic dysfunction, the small expression
alterations of two proteins involved in synaptic vesicle
trafﬁcking, the dynamin-1 isoform 1 and the charged
multivesicular body protein 4b, might be a speciﬁc early
consequences of A53T-SNCA overexpression. Alpha-syn-
uclein has been claimed to act as a chaperone for the
SNARE complex and thus modulate neurotransmitter
vesicle dynamics in the presynaptic compartment (Chandra
et al. 2005). Data from our mouse model and from other
alpha-synuclein mice suggest a scenario of progressive
synaptic failure, where SNARE proteins redistribute path-
ologically and neurotransmitter is no longer released
appropriately (Gillardon et al. 2008; Garcia-Reitbock et al.
2010), with concomitant pre- and postsynaptic changes in
the neurotransmitter biosynthesis, degradation and receptor
levels (Kurz et al. 2010). Thus, the two proteins identiﬁed
might represent this vesicle exocytosis/endocytosis/traf-
ﬁcking pathology.
Changes of proteins related to bioenergetics
In contrast, the apparent bioenergetic alteration is likely an
unspeciﬁc reﬂection of cell stress. Only the very early
increase of the triosephosphate isomerase might be spe-
ciﬁc, since loss-of-function mutations of this protein lead to
dystonia and neurodegenerative disease (Poll-The et al.
1985; Ahmed et al. 2003).
Regulation of protein aggregation markers
and the neurodegeneration marker GFAP
It is interesting that elevated expression of UCH-L1 was
found in the striatum of the old mice with manifest loco-
motor phenotype, since mutations affecting the activity of
UCH-L1 have previously been shown to constitute a risk
factor for the development of PD, leading to the recogni-
tion of the UCH-L1 gene as PARK5 (Leroy et al. 1998;
Setsuie and Wada 2007). The altered levels of three addi-
tional aggregation proteins is consistent with our previous
report about dysregulation of several gene transcripts
involved in alpha-synuclein aggregation at this age in the
striatum of these mice, such as Fkbp1a, Sept4, Tmeff2 and
the alpha-synuclein interactor Sncaip (Kurz et al. 2010),
and our demonstration of increased insolubility of alpha-
synuclein in old nigrostriatal tissue of these mice (Kurz
et al. 2010). This suggests that alpha-synuclein aggregation
is a feature of disease progression in these mice, becoming
apparent together with subtle signs of neurodegeneration
such as the GFAP upregulation observed. This upregula-
tion marks the hypertrophy of astrocytes in an effort to ﬁll
the gaps left behind by the insidious atrophy of neuronal
processes such as the dopaminergic presynapses in the
striatum.
Synopsis of alpha-synuclein overexpression triggered
proteome changes
Proteome studies have the potential to identify novel key
molecules in a pathological process such as PD (Licker
et al. 2009), but invariably represent only a small part of
the huge proteome complexity and are known to suffer
from low reproducibility. This is well illustrated by the
previous studies into proteomic consequences of alpha-
synuclein overexpression. In the Drosophila melanogaster
ﬂy model, a concordant expression change at the protein
and mRNA level was observed only for the GTP cyclo-
hydrolase gene (Xun et al. 2007b), which is involved in
dopamine biosynthesis together with the 14-3-3 proteins,
but this dysregulation at postnatal day 1 was no longer
observed at later ages. The protein showing the most
reproducibly altered levels at days 10, 30, 50 and 60 in the
same ﬂy model, elongation factor 1a48D, was reported
upregulated at two ages and downregulated at two ages
(Xun et al. 2007a). However, none of these changes reap-
peared when the same team studied the A53T mutant
instead of the A30P mutant (Xun et al. 2008). A concordant
upregulation of the levels of several ribosomal proteins in
this latter study contrasts with a reported downregulation of
several ribosomal proteins by human alpha-synuclein in
Caenorhabditis elegans (Ichibangase et al. 2008). This lack
of reproducibility is worsened by differing mutation
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well as a technical variance up to 33% just by inconsistent
sample preparation/fractionation and detection methods
(Baumann et al. 2005). Proteome studies of the mouse
brain have therefore focused on the carbonylated proteins
only (Poon et al. 2005) or on the synaptosomal proteins
only (Gillardon et al. 2008) and emphasized the importance
of mitochondrial protein pathology, in agreement with a
proteome study in mitochondrial fractions of a cell culture
model (Pennington et al. 2010).
In contrast, our study used non-fractionated striatal tis-
sue from the mouse brain, accepting the disadvantage that
synaptic/neural effects of A53T-alpha-synuclein overex-
pression would be diluted by the tissue heterogeneity and
in particular the glial proteome, increasing the threat of
false-negative data. In exchange, we sought to obtain the
overview and to elucidate, which effects of A53T-alpha-
synuclein overexpression dominate throughout the tissue at
early and late stages, thus enabling us to strengthen the
proteome data through independent validation by Western
blots and histology from brain tissue. The predominant
effect of A53T-alpha-synuclein overexpression on 14-3-3
levels in the striatum already at early age in our transgenic
mouse model is reﬂected by two independent proteome
studies of cells exposed to elevated alpha-synuclein. Rat
mesencephalic/neuroblastoma hybrid cells with alpha-
synuclein aggregation after oxidative stress were found to
have decreased 14-3-3 levels in Nonidet P-40 soluble
fractions, among many other effects such as altered chap-
erone levels (Zhou et al. 2004). In a separate investigation,
brain microglia cells cultured with recombinant nitrated
alpha-synuclein added to the medium displayed a reduction
of 14-3-3 protein levels, again besides effects on chaper-
ones and bioenergetics (Reynolds et al. 2009). Both cell
culture studies are compatible with the notion of a direct
interaction and sequestration of these proteins at short term.
According to our mouse study, in the long-term a tran-
scriptional regulation of 14-3-3 levels seems a main con-
sequence of alpha-synuclein gain-of-function. Thus, in
spite of inherent difﬁculties of proteome studies in animal
or cell models of disease, the altered levels of 14-3-3 in
response to alpha-synuclein toxicity seem to be among the
rare reproducible and validated ﬁndings.
Taken together, our data indicate that A53T-alpha-syn-
uclein overexpression in the mouse striatum early on leads
to a strong upregulation of 14-3-3 epsilon signaling toge-
ther with slight alteration of synaptic vesicle turnover and
glycolysis, while later the progression of toxicity is
apparent by the modest astrocyte proliferation and by
subtle elevation of protein aggregation molecules.
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